These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 25947159)

  • 21. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
    Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
    J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Kunjin Replicon Virus-like Particle Vaccine Provides Protection Against Ebola Virus Infection in Nonhuman Primates.
    Pyankov OV; Bodnev SA; Pyankova OG; Solodkyi VV; Pyankov SA; Setoh YX; Volchkova VA; Suhrbier A; Volchkov VV; Agafonov AA; Khromykh AA
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S368-71. PubMed ID: 25732811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ebola virus vaccines: an overview of current approaches.
    Marzi A; Feldmann H
    Expert Rev Vaccines; 2014 Apr; 13(4):521-31. PubMed ID: 24575870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early trials of Ebola vaccine show immune response.
    Mayor S
    BMJ; 2015 Apr; 350():h1844. PubMed ID: 25855620
    [No Abstract]   [Full Text] [Related]  

  • 25. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.
    Pratt WD; Wang D; Nichols DK; Luo M; Woraratanadharm J; Dye JM; Holman DH; Dong JY
    Clin Vaccine Immunol; 2010 Apr; 17(4):572-81. PubMed ID: 20181765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
    Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
    Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basic science and the Ebola virus infection epidemic.
    DeVane CL
    Pharmacotherapy; 2014 Nov; 34(11):1115-7. PubMed ID: 25382095
    [No Abstract]   [Full Text] [Related]  

  • 28. Ebola vaccine is safe and immunogenic, results show.
    Gulland A
    BMJ; 2015 Jan; 350():h524. PubMed ID: 25633684
    [No Abstract]   [Full Text] [Related]  

  • 29. Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop.
    Mire CE; Geisbert TW
    Trends Mol Med; 2017 Aug; 23(8):669-671. PubMed ID: 28697885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Overview of the Ebola vaccines in pre-clinical and clinical development].
    Buchy P
    Bull Soc Pathol Exot; 2016 Oct; 109(4):256-261. PubMed ID: 27646961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approaches to demonstration of Ebola virus vaccine efficacy.
    Krause PR; Cavaleri M; Coleman G; Gruber MF
    Lancet Infect Dis; 2015 Jun; 15(6):627-9. PubMed ID: 26008825
    [No Abstract]   [Full Text] [Related]  

  • 32. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
    Meyer M; Garron T; Lubaki NM; Mire CE; Fenton KA; Klages C; Olinger GG; Geisbert TW; Collins PL; Bukreyev A
    J Clin Invest; 2015 Aug; 125(8):3241-55. PubMed ID: 26168222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A glimpse into immune responses evolving against Ebola virus.
    Saphire EO
    Nat Med; 2019 Oct; 25(10):1470-1471. PubMed ID: 31591604
    [No Abstract]   [Full Text] [Related]  

  • 34. [Potential vaccine candidates against Ebola and the first vaccine against chikungunya virus infection].
    Nau JY
    Rev Med Suisse; 2014 Aug; 10(439):1570-1. PubMed ID: 25272676
    [No Abstract]   [Full Text] [Related]  

  • 35. The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms.
    O'Donnell K; Marzi A
    Expert Rev Vaccines; 2020 Mar; 19(3):267-277. PubMed ID: 32129120
    [No Abstract]   [Full Text] [Related]  

  • 36. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.
    Lai L; Davey R; Beck A; Xu Y; Suffredini AF; Palmore T; Kabbani S; Rogers S; Kobinger G; Alimonti J; Link CJ; Rubinson L; Ströher U; Wolcott M; Dorman W; Uyeki TM; Feldmann H; Lane HC; Mulligan MJ
    JAMA; 2015 Mar 24-31; 313(12):1249-55. PubMed ID: 25742465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ebola vaccine candidates are tested in humans.
    Hum Vaccin Immunother; 2014; 10(11):3103. PubMed ID: 25625922
    [No Abstract]   [Full Text] [Related]  

  • 38. Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention.
    Marcinkiewicz J; Bryniarski K; Nazimek K
    Folia Med Cracov; 2014; 54(3):39-48. PubMed ID: 25694094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection.
    Longet S; Mellors J; Carroll MW; Tipton T
    Front Immunol; 2020; 11():599568. PubMed ID: 33679690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Ebola Virus Vaccine Progress.
    Marzi A; Mire CE
    BioDrugs; 2019 Feb; 33(1):9-14. PubMed ID: 30604389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.